In this podcast, Lorenza Rimassa and Alejandro Forner summarize four abstracts orally presented during the ESMO annual congress held in Paris in September 2022.

Three abstracts report the results of first-line phase 3 trials of immunotherapy for unresectable hepatocellular carcinoma, and one trial reports the results of a phase 1/2 trial of a new FGFR inhibitor for cholangiocarcinoma.

HCC

LEAP-002 trial tested the combination of pembrolizumab and lenvatinib versus lenvatinib single agent and did not meet its primary endpoints. A second combination trial evaluated the combination of camrelizumab and rivoceranib versus sorafenib in a mostly Asian population showing the superiority of the combination compared to sorafenib, with a higher rate of adverse events. RATIONALE-301 assessed single-agent tislelizumab versus sorafenib demonstrating the non-inferiority of tislelizumab compared to sorafenib with a good safety profile.

CCA

The ReFocus study evaluated a new highly selective FGFR2 inhibitor in patients with cholangiocarcinoma with FGFR2 fusions previously treated with chemotherapy, showing impressive efficacy results and a good safety profile.

Incyte has co-funded this podcast and all content has been developed independently by ILCA.

In this podcast, Valerie Paradis and Maria Barcena Varela discuss four different papers presented at ILCA AC 2022. These interesting works have the aim to combine experimental models and studies of clinical patients and identify new cellular target based on immune cells. This will help to predict the response to immune therapy and understand the prognosis of HCC.

In this episode David Pinato comments on the ILCA 2022 session on Diagnosis, Imaging and Biomarkers for HCC. Hear his considerations and analysis on novel biomarkers, protein biomarkers and gut microbiomes as potential sources of clinical available biomarkers in the setting of early diagnosis of liver cancers.

Medical education is key to improve liver surgery as well as preparing surgical procedures and setting technological tools in advance. In this podcast Gonzalo Sapisochin and Eric Vibert will go through the surgical session at ILCA2022, summarising and commenting on the future of liver surgery for primary liver cancer.

Hear all about the preliminary results of a real-life study, a new and promising therapeutical approach to HCC, the final results from FIGHT-202 and new presented data from the Phase 3 HIMALAYA Trial. In this episode, Associate Professor at Humanitas University and IRCCS Humanitas Research Hospital, Lorenza Rimassa, and Medical Doctor at BCLC group, Marco Sanduzzi Zamparelli, summarise the abstracts presented in General Session 4 - Therapy & Miscellaneous & Clinical Trials in progress during #ILCA22.

In this episode, Transplant Hepatologist at Royal Prince Alfred Hospital, Ken Liu, and Professor of Medicine at UT Southwestern Medical Center, Amit Singal, cover some of the highlights from the General Session 2: Epidemiology, Staging and Prognosis of HCC at the ILCA Annual Conference 2022.

Join them as they discuss the latest data from the following abstracts:

· Efficacy of Local Treatment in Lymph Node Metastasis from Hepatocellular Carcinoma

· Evolution of Liver Transplantation for Hepatocellular Carcinoma in Europe. An Analysis of 32 858 cases from the European Liver Transplant Registry (ELTR).

· Variation in surveillance patterns and risk of HCC for sub-centimeter liver lesions on abdominal ultrasound

· Outcomes of Liver Transplantation in Non-Alcoholic Steatohepatitis (NASH) Versus Non-NASH Associated Hepatocellular Carcinoma

Hepatocellular carcinoma is a major health problem worldwide, being the fifth most common cancer and the third among cancer-related deaths. Surgery represents the cornerstone treatment for early stages, and Minimally Invasive Liver Surgery (MILS) has become an attractive option thanks to reduced intraoperative blood losses, shortened length of hospital stay, and similar oncological outcomes when compared to open liver resection. Nonetheless, the safety of MILS is still debated in challenging situations, such as in cirrhotic patients, difficult tumor locations, multiple or large tumors, and repeat resection.

In this podcast, Prof. Ho-Seong Han, professor of Surgery at Seoul National University College of Medicine, and renewed world leader in laparoscopic liver resection, discusses with his fellow Dr. Gianluca Cassese current indications of laparoscopic liver resection for HCC treatment in the light of its outcomes, focusing on technical aspects of minimally invasive anatomic liver resection.

In this episode, Drs. Amit Singal and Marco Sanduzzi-Zamparelli summarize presentations and the discussion from the ILCA Single Topic Workshop: HCC Risk Stratification and Surveillance, which was held in Paris, France on June 9-10, 2022.

The meeting and podcast covered a variety of topics including:

1. Risk stratification, including emerging clinical and biomarker-based risk models

2. Current status of primary prevention strategies for HCC

3. Factors impacting the efficacy versus effectiveness of HCC surveillance

4. Issues of surveillance underuse and potential interventions to increase adherence

5. Accuracy of current surveillance tools as well as status of alternative imaging and blood-based surveillance strategies

In this episode, authors Simone Khouzam and Duilio Pagano discuss the recently published research article "Protective benefit of minimally invasive liver surgery for hepatocellular carcinoma prior to transplant".

Examining the protective benefits of iterative surgical treatment of HCC prior to transplantation, surgeons at the ISMETT hospital in Palermo, Italy discuss the advantages of MILS for HCC and the importance of patient selection for intention to transplant. Given the complexity of HCC, the end goal remains to optimize the system to increase the number of patients transplanted.

Read full article: https://hrjournal.net/article/view/4666

Download full transcript here

In this podcast, Alejandro Forner summarised and commented some selected abstracts at the EASL Liver Cancer Summit 2022.

The following abstracts will be discussed:

1. Regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical practice: Exploratory analysis of safety and overall survival in the prospective, observational REFINE study. Finn R, et al. Liver Cancer Summit 2022 OS-55

2. Efficacy of combination therapy with lenvatinib, programmed cell death 1 inhibitors and transarterial therapy: a propensity score-matching cohort study. Wei Lu, et al. Liver Cancer Summit 2022 PO-119

3. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study.Thomas Talbot, et al. Liver Cancer Summit 2022 PO-128

4. Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma. Elia Gigante et al. Liver Cancer Summit 2022 PO-148

5. Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with advanced hepatocellular carcinoma: A real-world, multicentre, retrospective study. Guohong Han et al. Liver Cancer Summit 2022 PO-220

6. Liver transplantation for combined hepatocellular-cholangiocarcinoma: An analysis of the European Liver Transplant Registry. Marco Claasen et al. Liver Cancer Summit 2022 PO-308

7. Liver transplantation for fibrolamellar hepatocellular carcinoma: An analysis of the European Liver Transplant Registry. Marco Claasen et al. Liver Cancer Summit 2022 PO-313